Oral Glucokinase Activator Gets Breakthrough Tx Status for Type 1 Diabetes
TTP399 is an investigational oral, hepatoselective glucokinase activator.
TTP399 is an investigational oral, hepatoselective glucokinase activator.
The DARE-19 trial evaluated dapagliflozin in addition to standard of care in reducing disease progression, clinical complications and all-cause mortality in 1250 adults hospitalized with COVID-19.
Anavip contains venom-specific F(ab’)2 fragments of immunoglobulin G that bind and neutralize venom toxins.
Tepezza, a fully human monoclonal antibody, is approved for the treatment of thyroid eye disease.
Zegalogue is a glucagon analogue that is formulated in a ready-to-use aqueous solution for subcutaneous administration.
Almost one-third of older adults on thyroid replacement therapy take at least one medication that interferes with thyroid function tests
Physicians should screen overweight, obese adults aged 35 to 70 years and refer those with prediabetes to preventive interventions
VX-880 is an investigational allogeneic human stem cell-derived islet cell therapy that may restore pancreatic islet cell function.
Estimated change in mean body weight to week 68 was −9.6 percent with semaglutide 2.4 mg versus −3.4 percent with placebo
Tirzepatide is a novel, once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that integrates the actions of both incretins into a single molecule.